



## The usefulness of angiotensin-(1-7) and des-Arg<sup>9</sup>-bradykinin as novel biomarkers for metabolic syndrome

Akira Sugawara<sup>1</sup> · Hiroki Shimada<sup>1,2</sup> · Yuri Otsubo<sup>1</sup> · Takumi Kouketsu<sup>1</sup> · Susumu Suzuki<sup>1</sup> · Atsushi Yokoyama<sup>1</sup>

Received: 12 March 2021 / Revised: 8 April 2021 / Accepted: 12 April 2021 / Published online: 27 May 2021  
© The Japanese Society of Hypertension 2021

The renin–angiotensin system (RAS) and the kallikrein–kinin system (KKS) closely interact with each other [1, 2] (Fig. 1). In the RAS, angiotensinogen cleavage by renin generates angiotensin I, which is thereafter cleaved by angiotensin-converting enzyme (ACE) to form angiotensin II. Angiotensin II then binds to the angiotensin II type 1 (AT1) receptor, resulting in the induction of vasoconstriction, inflammation, apoptosis, hypertrophy, cell proliferation, fibrosis, and oxidative stress [3]. On the other hand, angiotensin-(1-7), which is generated by the cleavage of angiotensin II by ACE2, by the cleavage of angiotensin I by neprilysin (NEP), or by the cleavage of angiotensin-(1-9) by ACE/NEP, binds to the Mas receptor and induces vasodilatation, antiinflammation, antiremodeling, antihypertrophy, antiproliferation, antiapoptosis, and antioxidation effects [3, 4]. Recently, oral administration of angiotensin-(1-7) has been reported to prevent obesity and hepatic inflammation in rats fed a high-fat diet [5]. In the KKS, kallikrein forms bradykinin (BK) from kininogen [1, 2], and BK binds to the kinin B2 receptor and induces vasodilation, nitric oxide release, hypotension, antihypertrophy, and antiischemic effects [6, 7]. Moreover, BK-induced vasodilation has been shown to be augmented by angiotensin-(1-7) in spontaneously hypertensive rats [8]. BK is inactivated by ACE (also known as kininase II) via degradation into inactive fragments [2]. On the other hand, carboxypeptidase N (also known as kininase I) metabolizes BK into des-Arg<sup>9</sup>-BK [2, 6]. Des-Arg<sup>9</sup>-BK binds to the kinin B1 receptor and induces vasoconstriction, cell proliferation, and collagen synthesis [6, 7].

Recently, Fernandes et al. demonstrated that angiotensin-(1-7) and BK were inversely correlated with body mass index (BMI), while angiotensin I and des-Arg<sup>9</sup>-BK were positively correlated with BMI in adolescents, although angiotensin II did not show any correlation [9]. Moreover, while angiotensin-(1-7) and BK were inversely correlated with homeostasis model assessment, systolic blood pressure, and C-reactive protein, angiotensin I and des-Arg<sup>9</sup>-BK were positively correlated with these parameters [9]. Additionally, although angiotensin-(1-7) was inversely correlated with triglycerides, angiotensin I and des-Arg<sup>9</sup>-BK were positively correlated with them [9]. Interestingly, while leptin inversely was correlated with angiotensin-(1-7) and positively correlated with angiotensin I and des-Arg<sup>9</sup>-BK, adiponectin was positively correlated with BK [9]. Based on these data, the authors concluded that angiotensin-(1-7) and des-Arg<sup>9</sup>-BK may possibly be biological markers for adolescent obesity and therapeutic targets in the future [9]. In adipose tissues, all RAS components, including angiotensinogen, ACE, and ACE2, are locally expressed, and angiotensin I, angiotensin II, and angiotensin-(1-7) are produced in situ [10, 11]. Interestingly, adipocyte-specific ACE2 knockout female mice treated with a high-fat diet exhibited augmented obesity-induced hypertension, which was inversely correlated with the plasma angiotensin-(1-7)/angiotensin II ratio [12, 13]. Although ACE2 expression levels in visceral adipose tissues did not vary between control and obese patients [14], mouse experiments demonstrated that chronic exposure to a high-fat diet induced ADAM17 expression in adipose tissue, resulting in the shedding of ACE2 from the cell membrane of adipocytes [15]. We therefore hypothesize that the ACE2 activity in the adipocytes of metabolic syndrome patients may gradually decrease according to the duration of the condition, which may result in the reduction in angiotensin-(1-7) and the increase in des-Arg<sup>9</sup>-BK levels (Fig. 1).


ACE2 and angiotensin-(1-7) have recently been used as biomarkers of heart failure [16, 17]. Moreover, ACE2 has been recognized as a potential biomarker of coronary heart

✉ Akira Sugawara  
akiras2i@med.tohoku.ac.jp

<sup>1</sup> Department of Molecular Endocrinology, Tohoku University Graduate School of Medicine, Sendai, Japan

<sup>2</sup> Division of Pathology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan

**Fig. 1** Possible biomarkers for metabolic syndrome (MS) in the RAS and the KKS. Angiotensin I, ACE2, angiotensin-(1-7), BK, and des-Arg<sup>9</sup>-BK, which are candidate biomarkers, are underlined. Markers either upregulated (↑) or downregulated (↓) in MS are indicated



disease [18]. Interestingly, angiotensin-(1-7) has also been indicated as a potential biomarker for the diagnosis of Alzheimer's disease [19]. Additionally, changes in BK and des-Arg<sup>9</sup>-BK levels have recently been noticed as potential surrogate markers of the host response in antituberculosis treatment [20]. Although the recent study by Fernandes et al. first demonstrated the usefulness of angiotensin-(1-7) and des-Arg<sup>9</sup>-BK as biomarkers for obesity in adolescents [9], these biomarkers may also be useful for the diagnosis of the severity of adult metabolic syndrome in the future. Further studies are needed to expand their use to adult disorders.

## Compliance with ethical standards

**Conflict of interest** The authors declare no competing interests.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## References

1. Tschöpe C, Schultheiss HP, Walther T. Multiple interactions between the renin-angiotensin and the kallikrein-kinin systems: role of ACE inhibition and AT1 receptor blockade. *J Cardiovasc Pharm.* 2002;39:478–87.
2. Campbell DJ. The renin-angiotensin and the kallikrein-kinin systems. *Int J Biochem Cell Biol.* 2003;35:784–91.
3. Arroja MM, Reid E, McCabe C. Therapeutic potential of the renin angiotensin system in ischaemic stroke. *Exp Transl Stroke Med.* 2016;8:8.
4. Simões E, Silva AC, Teixeira MM. ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis. *Pharm Res.* 2016;107:154–62.
5. Santos SH, Andrade JM, Fernandes LR, Sinisterra RD, Sousa FB, Feltenberger JD, et al. Oral Angiotensin-(1-7) prevented obesity and hepatic inflammation by inhibition of resistin/TLR4/MAPK/NF-κB in rats fed with high-fat diet. *Peptides.* 2013; 46:47–52.
6. Sriramula S. Kinin B1 receptor: a target for neuroinflammation in hypertension. *Pharm Res.* 2020;155:104715.
7. Sharma JN. Does the kinin system mediate in cardiovascular abnormalities? An overview. *J Clin Pharm.* 2003;43:1187–95.
8. Fernandes L, Fortes ZB, Nigro D, Tostes RC, Santos RA, Catelli De Carvalho MH. Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studied in vivo. *Hypertension.* 2001;37:703–9.
9. Fernandes FB, Fernandes AB, Febba ACS, Leite APO, Leite CA, Vitale MSS, et al. Association of Ang-(1-7) and des-Arg<sup>9</sup>BK as new biomarkers of obesity and cardiometabolic risk factors in adolescents. *Hypertens Res.* 2021. <https://www.nature.com/articles/s41440-021-00618-0>.
10. Shimada H, Noro E, Suzuki S, Sakamoto J, Sato I, Parvin R, et al. Effects of adipocyte-derived factors on the adrenal cortex. *Curr Mol Pharm.* 2020;13:2–6.
11. Lelis DF, Freitas DF, Machado AS, Crespo TS, Santos SHS. Angiotensin-(1-7), adipokines and inflammation. *Metabolism.* 2019;95:36–45.

12. Gupte M, Thatcher SE, Boustany-Kari CM, Shoemaker R, Yiannikouris F, Zhang X, et al. Angiotensin converting enzyme 2 contributes to sex differences in the development of obesity hypertension in C57BL/6 mice. *Arterioscler Thromb Vasc Biol.* 2012;32:1392–9.
13. Shoemaker R, Tannock LR, Su W, Gong M, Gurley SB, Thatcher SE, et al. Adipocyte deficiency of ACE2 increases systolic blood pressures of obese female C57BL/6 mice. *Biol Sex Differ.* 2019;10:45.
14. Pinheiro TA, Barcala-Jorge AS, Andrade JMO, Pinheiro TA, Ferreira ECN, Crespo TS, et al. Obesity and malnutrition similarly alter the renin-angiotensin system and inflammation in mice and human adipose. *J Nutr Biochem.* 2017;48:74–82.
15. Gupte M, Boustany-Kari CM, Bharadwaj K, Police S, Thatcher S, Gong MC, et al. ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet. *Am J Physiol Regul Integr Comp Physiol.* 2008;295:R781–8.
16. Hisatake S, Kiuchi S, Kabuki T, Oka T, Dobashi S, Ikeda T. Serum angiotensin-converting enzyme 2 concentration and angiotensin-(1-7) concentration in patients with acute heart failure patients requiring emergency hospitalization. *Heart Vessels.* 2017;32:303–8.
17. Hisatake S, Kiuchi S, Kabuki T, Oka T, Dobashi S, Fujii T, et al. The serum angiotensin-converting enzyme 2 and angiotensin-(1-7) concentrations after optimal therapy for acute decompensated heart failure with reduced ejection fraction. *Biosci Rep.* 2020;40:BSR20192701.
18. Zhou X, Zhang P, Liang T, Chen Y, Liu D, Yu H. Relationship between circulating levels of angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis and coronary heart disease. *Heart Vessels.* 2020;35:153–61.
19. Jiang T, Tan L, Gao Q, Lu H, Zhu XC, Zhou JS, et al. Plasma angiotensin-(1-7) is a potential biomarker for Alzheimer's disease. *Curr Neurovasc Res.* 2016;13:96–9.
20. Qian X, Nguyen DTM, Li Y, Lyu J, Graviss EA, Hu TY. Predictive value of serum bradykinin and desArg<sup>9</sup>-bradykinin levels for chemotherapeutic responses in active tuberculosis patients: a retrospective case series. *Tuberculosis (Edinb).* 2016; 101S:S109–18.